Loading…

Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment

The mechanism of action of intravesical Mycobacterium bovis BCG immunotherapy treatment for bladder cancer is not completely known, leading to misinterpretation of BCG-unresponsive patients, who have scarce further therapeutic options. BCG is grown under diverse culture conditions worldwide, which c...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2022-12, Vol.11 (1), p.2051845-2051845
Main Authors: Guallar-Garrido, Sandra, Campo-Pérez, Víctor, Pérez-Trujillo, Míriam, Cabrera, Cecilia, Senserrich, Jordi, Sánchez-Chardi, Alejandro, Rabanal, Rosa Maria, Gómez-Mora, Elisabet, Noguera-Ortega, Estela, Luquin, Marina, Julián, Esther
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c534t-5ef76e0e3b77b22101a981988a788860a7c4175dd83eacfc7c2a91b2aeb8c6cb3
cites cdi_FETCH-LOGICAL-c534t-5ef76e0e3b77b22101a981988a788860a7c4175dd83eacfc7c2a91b2aeb8c6cb3
container_end_page 2051845
container_issue 1
container_start_page 2051845
container_title Oncoimmunology
container_volume 11
creator Guallar-Garrido, Sandra
Campo-Pérez, Víctor
Pérez-Trujillo, Míriam
Cabrera, Cecilia
Senserrich, Jordi
Sánchez-Chardi, Alejandro
Rabanal, Rosa Maria
Gómez-Mora, Elisabet
Noguera-Ortega, Estela
Luquin, Marina
Julián, Esther
description The mechanism of action of intravesical Mycobacterium bovis BCG immunotherapy treatment for bladder cancer is not completely known, leading to misinterpretation of BCG-unresponsive patients, who have scarce further therapeutic options. BCG is grown under diverse culture conditions worldwide, which can impact the antitumor effect of BCG strains and could be a key parameter of treatment success. Here, BCG and the nonpathogenic Mycobacterium brumae were grown in four culture media currently used by research laboratories and BCG manufacturers: Sauton-A60, -G15 and -G60 and Middlebrook 7H10, and used as therapies in the orthotopic murine BC model. Our data reveal that each mycobacterium requires specific culture conditions to induce an effective antitumor response. since higher survival rates of tumor-bearing mice were achieved using M. brumae-A60 and BCG-G15 than the rest of the treatments. M. brumae-A60 was the most efficacious among all tested treatments in terms of mouse survival, cytotoxic activity of splenocytes against tumor cells, higher systemic production of IL-17 and IFN-ɣ, and bladder infiltration of selected immune cells such as ILCs and CD4 TEM . BCG-G15 triggered an antitumor activity based on a massive infiltration of immune cells, mainly CD3 + (CD4 + and CD8 + ) T cells, together with high systemic IFN-ɣ release. Finally, a reduced variety of lipids was strikingly observed in the outermost layer of M. brumae-A60 and BCG-G15 compared to the rest of the cultures, suggesting an influence on the antitumor immune response triggered. These findings contribute to understand how mycobacteria create an adequate niche to help the host subvert immunosuppressive tumor actions.
doi_str_mv 10.1080/2162402X.2022.2051845
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_af55dc8e250440cb82eaa40ce64c7fce</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_af55dc8e250440cb82eaa40ce64c7fce</doaj_id><sourcerecordid>2645856132</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-5ef76e0e3b77b22101a981988a788860a7c4175dd83eacfc7c2a91b2aeb8c6cb3</originalsourceid><addsrcrecordid>eNp9UsFu1DAQjRCIVqWfAPKRS1rbiRPngkAVhZUWuIDEzZrY411XTlxsb6v9IX6A_-Cb8Ha3VXvBB89o5s2bsedV1WtGzxiV9JyzjreU_zzjlPNyCSZb8aw63sXrXeL5I_-oOk3pipbTUdE1w8vqqBGNEJ1kx9XvL1sdRtAZowNP0iZa0Ej0GuJdMJGIUzDo0ZBxS1Yx3OY10WE2LrswJ2Kiu0FinLUYcc4kb6YQazdb53OE7OYV0eh9IjAbkrYp4-Q0WVx-rf_-OV8sa9aXDh4hIXEzGT0Yg5FomHUxOSLkqdC-ql5Y8AlPD_ak-nH58fvF53r57dPi4sOy1qJpcy3Q9h1SbMa-HzlnlMEg2SAl9FLKjkKvW9YLY2SDoK3uNYeBjRxwlLrTY3NSLfa8JsCVuo5ugrhVAZy6C4S4UhCz0x4VWCGMlsgFbVuqR8kRoDjYtbq3GgvXuz3X9Wac0OjyjAj-CenTzOzWahVulBzEIKgsBG8PBDH82mDKanJp95kwY9gkxbtWSNGxhheo2EN1DClFtA9tGFU7yah7yaidZNRBMqXuzeMZH6ruBVIA7_eAstEQJ7gN0RuVYetDtLFsySXV_L_HP6_Q1oI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2645856132</pqid></control><display><type>article</type><title>Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment</title><source>Taylor &amp; Francis Open Access</source><source>PubMed Central</source><creator>Guallar-Garrido, Sandra ; Campo-Pérez, Víctor ; Pérez-Trujillo, Míriam ; Cabrera, Cecilia ; Senserrich, Jordi ; Sánchez-Chardi, Alejandro ; Rabanal, Rosa Maria ; Gómez-Mora, Elisabet ; Noguera-Ortega, Estela ; Luquin, Marina ; Julián, Esther</creator><creatorcontrib>Guallar-Garrido, Sandra ; Campo-Pérez, Víctor ; Pérez-Trujillo, Míriam ; Cabrera, Cecilia ; Senserrich, Jordi ; Sánchez-Chardi, Alejandro ; Rabanal, Rosa Maria ; Gómez-Mora, Elisabet ; Noguera-Ortega, Estela ; Luquin, Marina ; Julián, Esther</creatorcontrib><description>The mechanism of action of intravesical Mycobacterium bovis BCG immunotherapy treatment for bladder cancer is not completely known, leading to misinterpretation of BCG-unresponsive patients, who have scarce further therapeutic options. BCG is grown under diverse culture conditions worldwide, which can impact the antitumor effect of BCG strains and could be a key parameter of treatment success. Here, BCG and the nonpathogenic Mycobacterium brumae were grown in four culture media currently used by research laboratories and BCG manufacturers: Sauton-A60, -G15 and -G60 and Middlebrook 7H10, and used as therapies in the orthotopic murine BC model. Our data reveal that each mycobacterium requires specific culture conditions to induce an effective antitumor response. since higher survival rates of tumor-bearing mice were achieved using M. brumae-A60 and BCG-G15 than the rest of the treatments. M. brumae-A60 was the most efficacious among all tested treatments in terms of mouse survival, cytotoxic activity of splenocytes against tumor cells, higher systemic production of IL-17 and IFN-ɣ, and bladder infiltration of selected immune cells such as ILCs and CD4 TEM . BCG-G15 triggered an antitumor activity based on a massive infiltration of immune cells, mainly CD3 + (CD4 + and CD8 + ) T cells, together with high systemic IFN-ɣ release. Finally, a reduced variety of lipids was strikingly observed in the outermost layer of M. brumae-A60 and BCG-G15 compared to the rest of the cultures, suggesting an influence on the antitumor immune response triggered. These findings contribute to understand how mycobacteria create an adequate niche to help the host subvert immunosuppressive tumor actions.</description><identifier>ISSN: 2162-402X</identifier><identifier>ISSN: 2162-4011</identifier><identifier>EISSN: 2162-402X</identifier><identifier>DOI: 10.1080/2162402X.2022.2051845</identifier><identifier>PMID: 35355681</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Animals ; BCG ; Humans ; Immunotherapy ; innate immune response ; Innate-lymphoid cells ; Interleukin-17 ; lipid ; Mice ; Mycobacterium bovis ; non-muscle invasive ; Original Research ; tumor microenvironment ; Urinary Bladder ; Urinary Bladder Neoplasms - drug therapy</subject><ispartof>Oncoimmunology, 2022-12, Vol.11 (1), p.2051845-2051845</ispartof><rights>2022 The Author(s). Published with license by Taylor &amp; Francis Group, LLC. 2022</rights><rights>2022 The Author(s). Published with license by Taylor &amp; Francis Group, LLC.</rights><rights>2022 The Author(s). Published with license by Taylor &amp; Francis Group, LLC. 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-5ef76e0e3b77b22101a981988a788860a7c4175dd83eacfc7c2a91b2aeb8c6cb3</citedby><cites>FETCH-LOGICAL-c534t-5ef76e0e3b77b22101a981988a788860a7c4175dd83eacfc7c2a91b2aeb8c6cb3</cites><orcidid>0000-0002-6015-3282 ; 0000-0002-9666-5757 ; 0000-0002-8789-1883 ; 0000-0002-9521-791X ; 0000-0003-3161-9984 ; 0000-0002-9779-5940 ; 0000-0002-6919-7417 ; 0000-0001-6507-0673 ; 0000-0002-6558-3978 ; 0000-0002-8021-1718 ; 0000-0002-9941-6828</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959508/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959508/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27481,27903,27904,53769,53771,59119,59120</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35355681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guallar-Garrido, Sandra</creatorcontrib><creatorcontrib>Campo-Pérez, Víctor</creatorcontrib><creatorcontrib>Pérez-Trujillo, Míriam</creatorcontrib><creatorcontrib>Cabrera, Cecilia</creatorcontrib><creatorcontrib>Senserrich, Jordi</creatorcontrib><creatorcontrib>Sánchez-Chardi, Alejandro</creatorcontrib><creatorcontrib>Rabanal, Rosa Maria</creatorcontrib><creatorcontrib>Gómez-Mora, Elisabet</creatorcontrib><creatorcontrib>Noguera-Ortega, Estela</creatorcontrib><creatorcontrib>Luquin, Marina</creatorcontrib><creatorcontrib>Julián, Esther</creatorcontrib><title>Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment</title><title>Oncoimmunology</title><addtitle>Oncoimmunology</addtitle><description>The mechanism of action of intravesical Mycobacterium bovis BCG immunotherapy treatment for bladder cancer is not completely known, leading to misinterpretation of BCG-unresponsive patients, who have scarce further therapeutic options. BCG is grown under diverse culture conditions worldwide, which can impact the antitumor effect of BCG strains and could be a key parameter of treatment success. Here, BCG and the nonpathogenic Mycobacterium brumae were grown in four culture media currently used by research laboratories and BCG manufacturers: Sauton-A60, -G15 and -G60 and Middlebrook 7H10, and used as therapies in the orthotopic murine BC model. Our data reveal that each mycobacterium requires specific culture conditions to induce an effective antitumor response. since higher survival rates of tumor-bearing mice were achieved using M. brumae-A60 and BCG-G15 than the rest of the treatments. M. brumae-A60 was the most efficacious among all tested treatments in terms of mouse survival, cytotoxic activity of splenocytes against tumor cells, higher systemic production of IL-17 and IFN-ɣ, and bladder infiltration of selected immune cells such as ILCs and CD4 TEM . BCG-G15 triggered an antitumor activity based on a massive infiltration of immune cells, mainly CD3 + (CD4 + and CD8 + ) T cells, together with high systemic IFN-ɣ release. Finally, a reduced variety of lipids was strikingly observed in the outermost layer of M. brumae-A60 and BCG-G15 compared to the rest of the cultures, suggesting an influence on the antitumor immune response triggered. These findings contribute to understand how mycobacteria create an adequate niche to help the host subvert immunosuppressive tumor actions.</description><subject>Animals</subject><subject>BCG</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>innate immune response</subject><subject>Innate-lymphoid cells</subject><subject>Interleukin-17</subject><subject>lipid</subject><subject>Mice</subject><subject>Mycobacterium bovis</subject><subject>non-muscle invasive</subject><subject>Original Research</subject><subject>tumor microenvironment</subject><subject>Urinary Bladder</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><issn>2162-402X</issn><issn>2162-4011</issn><issn>2162-402X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>DOA</sourceid><recordid>eNp9UsFu1DAQjRCIVqWfAPKRS1rbiRPngkAVhZUWuIDEzZrY411XTlxsb6v9IX6A_-Cb8Ha3VXvBB89o5s2bsedV1WtGzxiV9JyzjreU_zzjlPNyCSZb8aw63sXrXeL5I_-oOk3pipbTUdE1w8vqqBGNEJ1kx9XvL1sdRtAZowNP0iZa0Ej0GuJdMJGIUzDo0ZBxS1Yx3OY10WE2LrswJ2Kiu0FinLUYcc4kb6YQazdb53OE7OYV0eh9IjAbkrYp4-Q0WVx-rf_-OV8sa9aXDh4hIXEzGT0Yg5FomHUxOSLkqdC-ql5Y8AlPD_ak-nH58fvF53r57dPi4sOy1qJpcy3Q9h1SbMa-HzlnlMEg2SAl9FLKjkKvW9YLY2SDoK3uNYeBjRxwlLrTY3NSLfa8JsCVuo5ugrhVAZy6C4S4UhCz0x4VWCGMlsgFbVuqR8kRoDjYtbq3GgvXuz3X9Wac0OjyjAj-CenTzOzWahVulBzEIKgsBG8PBDH82mDKanJp95kwY9gkxbtWSNGxhheo2EN1DClFtA9tGFU7yah7yaidZNRBMqXuzeMZH6ruBVIA7_eAstEQJ7gN0RuVYetDtLFsySXV_L_HP6_Q1oI</recordid><startdate>20221231</startdate><enddate>20221231</enddate><creator>Guallar-Garrido, Sandra</creator><creator>Campo-Pérez, Víctor</creator><creator>Pérez-Trujillo, Míriam</creator><creator>Cabrera, Cecilia</creator><creator>Senserrich, Jordi</creator><creator>Sánchez-Chardi, Alejandro</creator><creator>Rabanal, Rosa Maria</creator><creator>Gómez-Mora, Elisabet</creator><creator>Noguera-Ortega, Estela</creator><creator>Luquin, Marina</creator><creator>Julián, Esther</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6015-3282</orcidid><orcidid>https://orcid.org/0000-0002-9666-5757</orcidid><orcidid>https://orcid.org/0000-0002-8789-1883</orcidid><orcidid>https://orcid.org/0000-0002-9521-791X</orcidid><orcidid>https://orcid.org/0000-0003-3161-9984</orcidid><orcidid>https://orcid.org/0000-0002-9779-5940</orcidid><orcidid>https://orcid.org/0000-0002-6919-7417</orcidid><orcidid>https://orcid.org/0000-0001-6507-0673</orcidid><orcidid>https://orcid.org/0000-0002-6558-3978</orcidid><orcidid>https://orcid.org/0000-0002-8021-1718</orcidid><orcidid>https://orcid.org/0000-0002-9941-6828</orcidid></search><sort><creationdate>20221231</creationdate><title>Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment</title><author>Guallar-Garrido, Sandra ; Campo-Pérez, Víctor ; Pérez-Trujillo, Míriam ; Cabrera, Cecilia ; Senserrich, Jordi ; Sánchez-Chardi, Alejandro ; Rabanal, Rosa Maria ; Gómez-Mora, Elisabet ; Noguera-Ortega, Estela ; Luquin, Marina ; Julián, Esther</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-5ef76e0e3b77b22101a981988a788860a7c4175dd83eacfc7c2a91b2aeb8c6cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>BCG</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>innate immune response</topic><topic>Innate-lymphoid cells</topic><topic>Interleukin-17</topic><topic>lipid</topic><topic>Mice</topic><topic>Mycobacterium bovis</topic><topic>non-muscle invasive</topic><topic>Original Research</topic><topic>tumor microenvironment</topic><topic>Urinary Bladder</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guallar-Garrido, Sandra</creatorcontrib><creatorcontrib>Campo-Pérez, Víctor</creatorcontrib><creatorcontrib>Pérez-Trujillo, Míriam</creatorcontrib><creatorcontrib>Cabrera, Cecilia</creatorcontrib><creatorcontrib>Senserrich, Jordi</creatorcontrib><creatorcontrib>Sánchez-Chardi, Alejandro</creatorcontrib><creatorcontrib>Rabanal, Rosa Maria</creatorcontrib><creatorcontrib>Gómez-Mora, Elisabet</creatorcontrib><creatorcontrib>Noguera-Ortega, Estela</creatorcontrib><creatorcontrib>Luquin, Marina</creatorcontrib><creatorcontrib>Julián, Esther</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Oncoimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guallar-Garrido, Sandra</au><au>Campo-Pérez, Víctor</au><au>Pérez-Trujillo, Míriam</au><au>Cabrera, Cecilia</au><au>Senserrich, Jordi</au><au>Sánchez-Chardi, Alejandro</au><au>Rabanal, Rosa Maria</au><au>Gómez-Mora, Elisabet</au><au>Noguera-Ortega, Estela</au><au>Luquin, Marina</au><au>Julián, Esther</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment</atitle><jtitle>Oncoimmunology</jtitle><addtitle>Oncoimmunology</addtitle><date>2022-12-31</date><risdate>2022</risdate><volume>11</volume><issue>1</issue><spage>2051845</spage><epage>2051845</epage><pages>2051845-2051845</pages><issn>2162-402X</issn><issn>2162-4011</issn><eissn>2162-402X</eissn><abstract>The mechanism of action of intravesical Mycobacterium bovis BCG immunotherapy treatment for bladder cancer is not completely known, leading to misinterpretation of BCG-unresponsive patients, who have scarce further therapeutic options. BCG is grown under diverse culture conditions worldwide, which can impact the antitumor effect of BCG strains and could be a key parameter of treatment success. Here, BCG and the nonpathogenic Mycobacterium brumae were grown in four culture media currently used by research laboratories and BCG manufacturers: Sauton-A60, -G15 and -G60 and Middlebrook 7H10, and used as therapies in the orthotopic murine BC model. Our data reveal that each mycobacterium requires specific culture conditions to induce an effective antitumor response. since higher survival rates of tumor-bearing mice were achieved using M. brumae-A60 and BCG-G15 than the rest of the treatments. M. brumae-A60 was the most efficacious among all tested treatments in terms of mouse survival, cytotoxic activity of splenocytes against tumor cells, higher systemic production of IL-17 and IFN-ɣ, and bladder infiltration of selected immune cells such as ILCs and CD4 TEM . BCG-G15 triggered an antitumor activity based on a massive infiltration of immune cells, mainly CD3 + (CD4 + and CD8 + ) T cells, together with high systemic IFN-ɣ release. Finally, a reduced variety of lipids was strikingly observed in the outermost layer of M. brumae-A60 and BCG-G15 compared to the rest of the cultures, suggesting an influence on the antitumor immune response triggered. These findings contribute to understand how mycobacteria create an adequate niche to help the host subvert immunosuppressive tumor actions.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>35355681</pmid><doi>10.1080/2162402X.2022.2051845</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-6015-3282</orcidid><orcidid>https://orcid.org/0000-0002-9666-5757</orcidid><orcidid>https://orcid.org/0000-0002-8789-1883</orcidid><orcidid>https://orcid.org/0000-0002-9521-791X</orcidid><orcidid>https://orcid.org/0000-0003-3161-9984</orcidid><orcidid>https://orcid.org/0000-0002-9779-5940</orcidid><orcidid>https://orcid.org/0000-0002-6919-7417</orcidid><orcidid>https://orcid.org/0000-0001-6507-0673</orcidid><orcidid>https://orcid.org/0000-0002-6558-3978</orcidid><orcidid>https://orcid.org/0000-0002-8021-1718</orcidid><orcidid>https://orcid.org/0000-0002-9941-6828</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2162-402X
ispartof Oncoimmunology, 2022-12, Vol.11 (1), p.2051845-2051845
issn 2162-402X
2162-4011
2162-402X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_af55dc8e250440cb82eaa40ce64c7fce
source Taylor & Francis Open Access; PubMed Central
subjects Animals
BCG
Humans
Immunotherapy
innate immune response
Innate-lymphoid cells
Interleukin-17
lipid
Mice
Mycobacterium bovis
non-muscle invasive
Original Research
tumor microenvironment
Urinary Bladder
Urinary Bladder Neoplasms - drug therapy
title Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T20%3A25%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mycobacterial%20surface%20characters%20remodeled%20by%20growth%20conditions%20drive%20different%20tumor-infiltrating%20cells%20and%20systemic%20IFN-%CE%B3/IL-17%20release%20in%20bladder%20cancer%20treatment&rft.jtitle=Oncoimmunology&rft.au=Guallar-Garrido,%20Sandra&rft.date=2022-12-31&rft.volume=11&rft.issue=1&rft.spage=2051845&rft.epage=2051845&rft.pages=2051845-2051845&rft.issn=2162-402X&rft.eissn=2162-402X&rft_id=info:doi/10.1080/2162402X.2022.2051845&rft_dat=%3Cproquest_doaj_%3E2645856132%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c534t-5ef76e0e3b77b22101a981988a788860a7c4175dd83eacfc7c2a91b2aeb8c6cb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2645856132&rft_id=info:pmid/35355681&rfr_iscdi=true